# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Nuwellis shares are trading higher Monday after the company announced Friday that the first pediatric patient has been treated ...
Roth MKM analyst Jonathan Aschoff initiates coverage on Nuwellis (NASDAQ:NUWE) with a Buy rating and announces Price Target ...
QUELIMMUNE, Manufactured For SeaStar Medical And Licensed By Nuwellis, Targets Pediatric AKI Patients With Sepsis Requiring Kid...
Nuwellis, Inc. (NASDAQ:NUWE) ("Nuwellis" or the "Company"), a medical technology company focused on transformin...